Patheon — Q3 2011 Earnings Presentation
15 slides from Patheon's earnings presentation, Sep 9, 2011
Slide 1: Fiscal 2011 Third Quarter Earnings
Exhibit 99.2 September Patheon Fiscal 20112011 Third Quarter Earnings
Slide 2: Forward-Looking Statements
Forward-Looking This and uncertainties 10-Q Accordingly, 2These opportunities. presentation and forward-looking Formthat you10, may contains are Statements All ascautioned statements, amended, cause statements forward-looking ournot and actual other are toour place made results than other statements
Slide 3: Third Quarter and Nine Month Highlights
3Third Quarter and Nine Month Highlights
Slide 4: Historical performance highlights the need for improvement across our business
Poor 1000 Revenues Operating 40 Cash 60 0$Net 2008 4*LTM in40 -535 Loss millions -10 historical 800 2009 Flow 30 20 = -15 Last 25 0600 Income 2010 From -20 20twelve 400 performance 15LTM* Operations 200 10 months 500 highlights the need for improvement across our business
Slide 5: Our Current Strategy: Strengthen Core Businesses
Our Current Strengthen Next 1. •2. 53. Additional Transformation Site Discontinuing Focus Drive Increase strategy step: actions focus: efficiency our Sell the core OE will network include operational business activities operations efforts underway begin improvements Caguas, footprint planned with di
Slide 6: Patheon enjoys a top position across highly fragmented CMO and CDO markets
CMO$100 400+ Patheon Vetter Baxter Famar Aenova Fareva Haupt DPT Recipharm Hospira Nextpharma Catalent CDO Patheon, Catalent, Lancaster Aptuit AAI, Almac, PPD 100+ 6Source: 2% $75 Others Others, Market Market 4% 3% 3% $75 4% 3% $100 PharmSource 3% 2% enjoys 5% 13% $126 $35 Labs, 2% 2% 54% $690 a$100
Slide 7: CMO Market Size Forecast: Conservative, Base-Case, Upside
CMO $16.0 2011 $11.6 $11.4 $11.1 Conservative Base-Case Upside 7•Strategic The Furthermore, Grow 2012 market path $12.2 $11.9 $11.2 $14.0 market Market (5%-6% business Implications for 2013 (3%-5% $12.4 $11.3 $12.9 $12.0 for (~1% is Size, growth price expected Annual 2014 by commodity $11.4 $12.9 $1
Slide 8: Our Key CMO Market Assessment Findings
Our Key CMO 8–•PDS The Customers Pharma Despite CAPEX PDS Emerging Larger Offering Findings market global offerings companies companies declining investments companies seek development for Must From need commodity partners Reflect R&D Market that do outsource toare that not be outsource spending, pi
Slide 9: Five Commitments to Transform Ourselves
954321We We Our Must will factories Pharmaceutical Make provide create operate must Five a our the culture Commitments be business industry’s Development theofhighest engagement, inleading a disciplined, quality, to Services Transform customer ownership most will responsible, flexible, Ourselves pro
Slide 10: The CMO Strategy Builds on Three Pillars
The Focus Consolidate Build Set •Focus •Increase Drive •Broaden Exceed 10 Add Focus Meet Build Identify the CMO New high for and customer footprint foundation competitive flexibility sites the overall excellence talent Transform Strategy value, Capabilities the offering on to Network center on deman
Slide 11: Optimizing Our Facility Footprint
Optimizing Caguas Zug Burlington Swindon 11 Transferring Previously Assessing Consolidation our facility EU announced strategic headquarters footprint of QC alternatives closure into operations Toronto underway for the and to site; UK pending Whitby PDSfinal sites; operations regulator assessing wil
Slide 12: Centers of Excellence
We •The CoE 12 Aseptic Very Focus Create Specialty Investments High Investment Improve More New Will “Center 1 high 5 allow capabilities CoE potency volume automation site the Operate filling sterile each solid volume, 62missions ability of to CoE toand have Excellence” and allow and site enable dos
Slide 13: The PDS Strategy Rests on Three Pillars
The Late Early Growth Build •Add •Bolster •Strengthen Grow •Scale Primary 13 Secure Expand Globalize Optimize Identify PDS Development capabilities Development the the& driver our Business Strategy the Brand Foundation talent Transformation capabilities PDS feeder technical leading franchise oftofoo
Slide 14: PDS Reorganized: Early and Late Phase Operations
–•PDS 14 Reorganized Operational Late Early Strengthen Opening Planning strategy phase phase of toclinical our implementation our investments Excellence increase into talent new global operations San our base isteams for capabilities Francisco cornerstone toboth drive capabilities centered new into
Slide 15: Our Commitment to Top Quartile Industry Performance
Our quartile Industry Customer-focused Technology Employee Shareholder Partner Known Clear Solution Recognized Top 15 actions and of for leading provider regular choice commitment expertise and solutions as return performers leading impact efficiency savings forand early place will have providing fr